ArticleArchives of rheumatology2025
Association Between Levels of N-Terminal Pro-brain Natriuretic Peptide and Coronary Artery Lesion in Patients with Kawasaki Disease: A Systematic Review and Meta-analysis.
Article in Archives of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Kawasaki disease (KD) is often complicated by coronary artery lesions (CAL). Identifying reliable biomarkers may improve early diagnosis and risk stratification for CAL, facilitating timely intervention. This study aims to investigate the diagnostic value of N-terminal pro-brain natriuretic peptide (NT-proBNP) in KD complicated with CAL. Materials and Methods: PubMed, Scopus, Web of Science, Embase, and the Cochrane Library databases were searched from inception to November 30, 2024 for English-language studies comparing NT-proBNP levels in KD patients with and without CAL. Diagnostic accuracy metrics for NT-proBNP in detecting CAL were also analyzed. The analysis was performed using a random-effects model. I² statistics assessed the heterogeneity. NT-proBNP levels reported as medians were converted to means using established formulas. Results: Nineteen studies involving 9017 participants showed significantly higher NT-proBNP levels in KD patients with CAL (pooled standardized mean differences = 1.889, 95% CI: 1.274 to 2.504, P < .001), with substantial heterogeneity (I² = 98.5%). Eighteen studies assessed diagnostic accuracy, yielding pooled sensitivity and specificity of 0.78 (95% CI: 0.68-0.85) and 0.78 (95% CI: 0.70-0.84), respectively. The diagnostic odds ratio was 12 (95% CI: 7-21), with an area under the receiver operating characteristic curve (AUROC) of 0.85 (95% CI: 0.81-0.88), indicating good diagnostic performance. However, heterogeneity remained significant (I² = 99%). Conclusion: N-terminal pro-brain natriuretic peptide is a promising biomarker for detecting CAL in KD, with good diagnostic accuracy. While elevated NT-proBNP levels correlate with CAL, its role is best realized as part of a multimodal diagnostic approach. Future research should focus on standardization and validation across diverse populations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.